Please login to the form below

Not currently logged in
Email:
Password:

MethylGene appoints Peggy Mulligan as director

Former chief financial officer at Valeant to join Canada-based biotech

Former chief financial officer of Valeant Pharmaceuticals Peggy Mulligan has joined the board of directors at Canada-based MethylGene.

Charles Grubsztajn, president and CEO of the small molecule drug development company, highlighted Mulligan's experience in finances and auditing as reasons for her appointment.

“We look forward to her guidance as we plan for the future,” he said.

Mulligan had previously been chief financial officer and executive VP at Biovail before its merger with Valeant in September 2010 in which she played a key role, co-leading the merger and subsequent integration between the two companies.

She resigned from Valeant in December 2010, just three months after the merger, to pursue other interests.

Prior to her time at Biovail/Valeant, Mulligan served as executive VP and chief financial officer and treasurer of Linamar Corporation from 2005 to 2007.

Previously, she spent eleven years in various roles at the Bank of Nova Scotia, most recently as executive VP, systems and operations.

In 2003 and 2004 Mulligan was also named one of Canada's Top 100 Most Powerful Women by the Women's Executive Network.

21st March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics